Pennon Group (PNNl)

BATS Europe


	Symbol		Exchange		Currency
	PNN		London		GBP	Real-time
	PNNl		BATS Europe		GBP	Delayed
	PEGRY		OTC Markets		USD	Delayed

Currency in GBP

Disclaimer

547.50

-13.50(-2.41%)

Closed09/10

Fair Value

Day's Range

543.50

563.50

52 wk Range

543.50

774.50

Pennon (PNNl) Income Statement & Profits

Assess the Pennon Income Statement (earnings report), showing the company's financial performance from operating and non operating activities such as revenue, expenses and income. Check assets and liabilities, diluted earnings per share (EPS), and net income after taxes for the last 4 periods (either quarterly or annually).

Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.

Advanced Income Statement

Period Ending:

2015

31/03

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

Total Revenues

635.7

623.1

791.3

796.2

906.8

Total Revenues Growth

+1.94%

-1.98%

+26.99%

+0.62%

+13.89%

Total Operating Expenses

398.7

433.5

554.5

685.2

741.7

	Operating Expenses Growth
	Fuel & Purchased Power
	Operations And Maintenance
	Depreciation & Amortisation, Total
	Other Operating Expenses, Total

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+6.01%	+8.73%	+27.91%	+23.57%	+8.25%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	119.8	119.4	146.7	154.7	172
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	278.9	314.1	407.8	530.5	569.7

Operating Income

237

189.6

236.8

111

165.1

Operating Income Growth

-4.24%

-20%

+24.89%

-53.13%

+48.74%

EBIT Margin %

37.28%

30.43%

29.93%

13.94%

18.21%

Interest Expense, Total

-63.7

-58.3

-94.2

-142.1

-157

Other Non Operating Expenses, Total

15.3

-3.5

-2.1

17.3

-1.3

	Income (Loss) on Equity Investment
	Allowance For Equity Funds Used During Construction
	Other Non Operating Income (Expenses)

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	0.3	0.7
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	15.3	-3.5	-2.1	17	-2

EBT, Excl. Unusual Items

192.7

132

142.5

-8.9

13.9

Gain (Loss) on Sale of Investments

-

-

-

-

-

Gain (Loss) On Sale Of Assets

0.4

0.1

1

0.4

0.8

EBT, Incl. Unusual Items

193.1

132.1

127.7

-8.5

-9.1

EBT, Incl. Unusual Items Growth

-4.12%

-31.59%

-3.33%

-106.66%

-7.06%

Income Tax Expense

70.6

24.8

112.1

-8.9

-0.6

Net Income to Company

206.3

1,762

15.6

0.4

-8.5

Minority Interest

1.1

0.2

-0.2

-0.3

-1

Net Income

207.4

1,762.2

15.4

0.1

-9.5

Net Income Growth

-6.95%

+749.66%

-99.13%

-99.35%

-9,600%

Net Income Margin %

32.63%

282.81%

1.95%

0.01%

-1.05%

Preferred Dividend and Other Adjustments

7

-

-

-

-

Net Income to Common Excl. Extra Items

116.6

107.5

15.4

0.1

-9.5

Basic EPS - Continuing Operations

0.42

0.38

0.05

0

-0.04

Basic EPS - Continuing Operations Growth

-27.37%

-8%

-87.11%

-99.23%

-9,452.49%

Diluted EPS - Continuing Operations

0.41

0.38

0.05

0

-0.04

Diluted EPS - Continuing Operations Growth

-27.56%

-7.97%

-87.14%

-99.22%

-9,573.68%

Basic Weighted Average Shares Outstanding

280.13

280.73

312.1

261.9

266.6

Diluted Weighted Average Shares Outstanding

281.4

281.8

313.8

262.8

266.6

Dividend Per Share

0.66

0.33

0.39

0.43

0.44

Dividend Per Share Growth

+6.61%

-50.34%

+18.15%

+10.9%

+3.84%

EBITDA

310.8

277.2

345.7

229.3

298.7

EBITDA Growth

-29.79%

-10.81%

+24.71%

-33.67%

+30.27%

EBITDA Margin %

48.89%

44.49%

43.69%

28.8%

32.94%

EBIT

237

189.6

236.8

111

165.1

* In Millions of GBP (except for per share items)

8,243.74

+53.13

+0.65%

19,254.93

+188.46

+0.99%

4,982.15

+33.15

+0.67%

5,792.00

+40.90

+0.71%

39,430.00

+130.50

+0.33%

42,512.00

+431.63

+1.03%

FTSE 100 Futures

8,311.70

+2.5

+0.03%

Name	Last	Chg. %	Vol.
BP	406.40	-0.01%	25.40M
HSBC	669.40	+0.51%	15.26M
GSK plc	1,458.00	+0.34%	8.11M
Shell	2,586.0	+0.39%	7.51M
CRH	6,844.0	+1.48%	3.29M
Rio Tinto PLC	5,048.0	+0.08%	1.92M
AstraZeneca	11,756.0	+0.67%	945.73K